568 件 ・ 関連度順
概要と使いどころ
Set up and run reinforcement learning with verifiable rewards (RLVR/GRPO) for math, code, or custom environments using the Tinker API. Use when the user wants to do RL training, GRPO, reward-based optimization, or train with verifiable rewards.
日本語の概要は準備中です。原文の説明を表示しています。
RSA ve crypto için kafes (lattice) tabanlı saldırılar — Coppersmith, LLL/BKZ, Boneh-Durfee, Hastad broadcast, Franklin-Reiter, stereotyped message
日本語の概要は準備中です。原文の説明を表示しています。
Provides cryptography attack techniques for CTF challenges. Use when attacking encryption, hashing, signatures, ZKP, PRNG, or mathematical crypto problems involving RSA, AES, ECC, lattices, LWE, CVP, number theory, Coppersmith, Pollard, Wiener, padding oracle, GCM, key derivation
日本語の概要は準備中です。原文の説明を表示しています。
Manim CE animations: 3Blue1Brown math/algo videos.
日本語の概要は準備中です。原文の説明を表示しています。
Busabase-backed App-in-Skill control-panel/workspace for a deal analyst to model revenue-based-financing (RBF) deals for SME businesses (retail/F&B chain stores). Use when the user invokes $kelly-revshare-simulator or /kelly-revshare-simulator, wants to model a revenue-share or merchant-cash-advance deal, project cash flow and repayment, compute a Cash-Flow Payout Multiple, effective annualized merchant cost, or compare/underwrite multiple financing scenarios. Pure deterministic math, no external calls, no real trading/payment side effects. Scenario create/edit/delete and the underwriting decision are direct writes made by the analyst, not a review/approval queue.
日本語の概要は準備中です。原文の説明を表示しています。
Pick the right y-axis unit when creating or updating a TrendsQuery insight via `posthog:insight-create` or `posthog:insight-update`. Use when the agent is about to add a `formula` purely to convert units (e.g. dividing seconds by 60 to display minutes), when a `math_property` is a duration, currency, ratio, or large count, or whenever the user mentions "format the y-axis", "duration", "seconds", "minutes", "hours", "milliseconds", "ms", "percentage", "currency", "decimals", "axis label", or "axis unit" in the context of a graph insight.
日本語の概要は準備中です。原文の説明を表示しています。
Strategic clinical trial design feasibility assessment. Analyzes 6 dimensions (endpoint, population, comparator, effect size, duration, regulatory pathway) using precedent trials and FDA guidance. Produces enrollment projections, endpoint recommendations, and approval-pathway analysis. Use for trial-protocol design, power/sample-size estimation, comparator selection, and FDA submission strategy. Driven by precedent-based reasoning rather than first-principles math.
日本語の概要は準備中です。原文の説明を表示しています。
Solve ordinary differential equations (initial and boundary value problems). Supports stiff/non-stiff systems, event detection, Hamiltonian/symplectic integration, parameter sweeps, and phase space analysis. Use for any ODE system in physics, engineering, or applied math.
日本語の概要は準備中です。原文の説明を表示しています。
Merge multiple fine-tuned models using mergekit to combine capabilities without retraining. Use when creating specialized models by blending domain-specific expertise (math + coding + chat), improving performance beyond single models, or experimenting rapidly with model variants. Covers SLERP, TIES-Merging, DARE, Task Arithmetic, linear merging, and production deployment strategies.
日本語の概要は準備中です。原文の説明を表示しています。
実行可能性（feasibility）を確認する。問題の複雑度に応じて一発解きor段階的解法を選ぶ
受け取ったデータから最適化問題の構造を把握し、仮説を立てる。最も重要なスキル。
ボトルネックに合わせた改善策を設計・実行・検証する
追加データの依頼書を生成する。何がなぜ必要かを非技術者向けに説明
最適化モデルの運用設計。自動化・監視・フォールバックを定義する
最適化結果を非技術者にも伝わる改善提案書にまとめる
Infers person-to-person transmission from pathogen genomes using outbreaker2 (Campbell 2018), TransPhylo (Didelot 2017), phybreak (Klinkenberg 2017), BadTrIP (De Maio 2018), SCOTTI (De Maio 2016), BEASTLIER (Hall 2015), and SNP-distance / cluster-picker approaches (HIV-TRACE for HIV; transcluster). Defines outbreak clusters using pathogen-specific SNP thresholds (NOT a universal cutoff -- TB <=12 SNPs / Walker 2013; MRSA <=15 / Coll 2017; C. difficile <=2 / Eyre 2013; Klebsiella <=21 / Snitkin 2012), models within-host diversity and transmission bottlenecks (Worby-Lipsitch-Hanage 2014; McCrone 2018; Sobel Leonard 2017; Lythgoe 2021 SARS-CoV-2), integrates contact-tracing data, distinguishes generation interval from serial interval (Britton & Scalia Tomba 2019; Ali 2020), attributes source via Bayesian source attribution (Mather 2013 DT104; islandR), and reconciles transmission-network reconstruction with epi metadata. Use when investigating outbreaks for who-infected-whom, defining SNP-cluster outbreak definitions, accounting for unsampled intermediates, choosing between outbreaker2 (rich epi data) and TransPhylo (genomic-only after dated phylogeny), running source attribution between host populations, calling HIV-TRACE thresholds appropriate to the local subtype, or distinguishing recent transmission from reactivation in TB / chronic HIV.
日本語の概要は準備中です。原文の説明を表示しています。
Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes pooled prime-editor (PE) screens for installing precise genetic variants without bystander confounding. Covers pegRNA design with PRIDICT and PRIDICT2 (Mathis 2023/2024) for predicting per-pegRNA editing efficiency, pegRNA architecture (spacer + scaffold + PBS + RTT), PE2 / PE3 / PE3b / PEmax / PEAR variants, MOSAIC in situ saturation mutagenesis (Hsu JY et al 2024 bioRxiv), the PRIME pooled-screen methodology (Erwood/Doman 2023 Nat Biotechnol 41:885; ~3,699 ClinVar variant screens), chromatin context as a primary determinant of PE efficiency, scaffold-incorporation and indel byproduct quantification with CRISPResso2, and the cross-modal validation strategy of PE + base-editor screens for variant function. Use when designing a pegRNA library for variant installation, choosing between BE and PE for a specific edit, predicting pegRNA efficiency before library synthesis, analyzing PE screen output, distinguishing intended-edit from scaffold-incorporation, or scaling PE screens to thousands of variants.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes in vivo CRISPR screens in animal tumor models, organoids, and immune-cell adoptive transfers. Covers bottleneck math (250x cells/sgRNA requires ~25M cells implanted; impossible for most syngeneic models, forcing focused libraries), focused library design (Manguso 2017 Nature 547:413 immune screen; Chen 2015 tumor screens), CRISPR-StAR intrinsic-control screening (Uijttewaal 2025 Nat Biotechnol 43:1848), clonal-dynamics-limited detection, tumor-explant DNA recovery, syngeneic vs xenograft vs PDX considerations, and the relationship to downstream MAGeCK / drugZ analysis. Use when designing in vivo CRISPR screens for tumor / immune / metastasis biology, choosing focused vs genome-wide for animal models, addressing bottleneck-induced clonal collapse, picking the syngeneic / xenograft / PDX model, integrating in vivo with in vitro results, or applying CRISPR-StAR for animal experiments.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes CRISPR drug-modifier (chemogenomic) screens with drugZ (Li & Hart 2019 Genome Med), a bidirectional Z-score method that identifies synthetic-lethal sensitizing genes and resistance-conferring suppressor genes from vehicle vs drug comparisons. Covers vehicle-anchored design (not Day-0), the bidirectional Z math giving 2-3x sensitivity over MAGeCK / STARS / edgeR / RIGER on drug screens, per-gene sumZ and normZ, synth (sensitizer) vs supp (suppressor) FDR, multi-dose handling, integration with control sgRNAs, and comparison with MAGeCK MLE with dose covariate. Use when running a drug-modifier CRISPR screen, identifying sensitizing or resistance genes for a drug candidate, choosing drugZ vs MAGeCK MLE for chemogenomic analysis, troubleshooting low-effect drug screens where MAGeCK lacks sensitivity, or designing a drug-screen layout (vehicle vs drug arms).
日本語の概要は準備中です。原文の説明を表示しています。
Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes base-editing screens for variant function. Covers library design (Sanson 2020 GRACE, Hanna 2021 BRCA1/2 SNV scanning, Cuella-Martin 2021), CBE vs ABE chemistry choice (BE3/BE4 vs ABE7.10/ABE8.20/ABE8e), editing-window math (positions 4-8 from PAM-distal end, wider for ABE8e), bystander-edit quantification and the variant-call ambiguity it creates, sgRNA-efficiency filtering before hit calling, indel byproduct interpretation, the substitution-vs-indel diagnostic, variant annotation against ClinVar / COSMIC, and the Broad be-validation-pipeline. Use when designing a BE variant screen, choosing CBE vs ABE for a specific edit, interpreting bystander-confounded hits, distinguishing functional signal from indel artifact, integrating CRISPResso2 output with screen scoring, or deciding BE vs PE for SNV installation.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill when the user asks about trucking rate negotiation — cost-plus pricing, market rate benchmarking via DAT/Truckstop, fuel surcharge math, how to negotiate with brokers/shippers, when to walk away, contract pricing vs spot rates. Reference DAT Rate Analytics + freight market reports.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill when the user asks about truck purchase financing, leasing options, factoring, fuel surcharge math, lease-purchase agreements, the total-cost-of-ownership (TCO) comparison between buying + leasing, and how owner-operators finance their first truck. Cover Section 179 + Bonus Depreciation tax treatment.
日本語の概要は準備中です。原文の説明を表示しています。